Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
2
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Target Indication
Metastatic Non Small Cell Lung Cancer
Clinical Trial
NCT05215340Last updated: 12/23/2025
Datopotamab deruxtecan Daiichi Sankyo
Treatment of adult patients with locally advanced or metastatic non squamous non-small cell lung cancer (NSCLC)
View on EMADatroway
Breast cancerDatroway as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine therapy and at least one line of chemotherapy in the advanced setting.
View on EMA